TVTX Company Profile and Key Details
Travere Therapeutics, Inc.
TVTX Stock Price Chart
Stock Price Today
Travere Therapeutics, Inc. (TVTX) stock remained unchanged at $19.46 a share on NASDAQ. The stock opened at $19.46, fluctuating between $18.54 to $19.69 during the session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company Information
| Employees | 380 |
| Beta | 0.7 |
| Sales or Revenue | $145.24M |
| 5Y Sales Change% | -0.519% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Travere Therapeutics, Inc. (NASDAQ: TVTX) stock price is $19.46 in the last trading session. During the trading session, TVTX stock reached the peak price of $19.69 while $18.54 was the lowest point it dropped to. The percentage change in TVTX stock occurred in the recent session was 0% while the dollar amount for the price change in TVTX stock was -.
The NASDAQ listed TVTX is part of Biotechnology industry that operates in the broader Healthcare sector. Travere Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. William E. Rote Ph.D.
Senior Vice President of R&D
Mr. Christopher Cline C.F.A., CFA
Chief Financial Officer
Mr. Peter Heerma
Chief Commercial Officer
Ms. Charlotte Smith
Senior Vice President of Public Affairs
Dr. Jula Inrig M.D.
Chief Medical Officer
Mr. Casey Logan
Senior Vice President of Corporation & Bus. Devel.
Ms. Angela Giannantonio
Senior Vice President of HR
Ms. Sandra Calvin
SVice President, Corporation Controller & Chief Accounting Officer
Dr. Noah L. Rosenberg M.D.
Executive Advisor
Ms. Elizabeth E. Reed
Senior Vice President, Gen. Counsel & Corporation Sec.
Dr. Eric M. Dube Ph.D.
Pres, Chief Executive Officer & Director
TVTX's closing price is 280.08% higher than its 52-week low of $5.12 where as its distance from 52-week high of $20.33 is -4.28%.
Number of TVTX employees currently stands at 380.
Official Website of TVTX is: https://www.travere.com
TVTX could be contacted at phone 888 969 7879 and can also be accessed through its website. TVTX operates from 3611 Valley Centre Drive, San Diego, CA 92130, United States.
TVTX stock volume for the day was 1.69M shares. The average number of TVTX shares traded daily for last 3 months was 1.3M.
The market value of TVTX currently stands at $1.69B with its latest stock price at $19.46 and 87.03M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com